pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›YESAFILI
drug · protein
save

YESAFILI

Marketedupdated 3mo ago
by $HCWB HCW Biologics Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • drugEYLEA HD18 co-mentions · 7 sources
  • tagApproval18 co-mentions · 7 sources
  • drugEylea14 co-mentions · 7 sources
  • drugaflibercept biosimilar9 co-mentions · 7 sources
  • companyBiocon Biologics Ltd4 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.

targets

Placenta growth factorVascular endothelial growth factor A, long form

all catalysts(2)

approval · 2
May 20, 2024
approval
$HCWB
2y ago
YESAFILI (AFLIBERCEPT-JBVF) — FDA approval
YESAFILI
→
Jan 13, 2026
approval
$HCWB
7mo ago
YESAFILI (AFLIBERCEPT-JBVF) — FDA approval
YESAFILI
→

News(10)

  • Regeneron to challenge Ipsen as FDA clears bone disease drug
    Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
    biopharma_dive · 21h ago
  • EyePoint’s bid to compete with Eylea falls flat
    EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…
    endpoints · 3d ago
  • EyePoint plummets on pivotal data for main drug
    Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
    biopharma_dive · 3d ago
  • EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
    EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
    biospace · 3d ago
  • Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
    Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
    biospace · 10d ago
  • Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
    Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
    fiercebiotech · 11d ago
  • Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
    Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
    biospace · 21d ago
  • FDA scientists question Capricor data; Legend CEO steps down
    Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
    biopharma_dive · 24d ago
  • Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
    Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
    fiercebiotech · 29d ago
  • ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
    biopharma_dive · 1mo ago
view all news mentions →
brand
YESAFILI
trade names
Eylea, Yesafili, Zaltrap
generic
AFLIBERCEPT-JBVF
MOA
Placenta growth factor inhibitor; Vascular endothelial growth factor A inhibitor
indication
glaucoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?